^
Association details:
Biomarker:TMB-H
Cancer:Soft Tissue Sarcoma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
03/13/2023
Excerpt:
Soft tissue sarocma...Subsequent Lines of Therapy for Advanced/Metastatic Disease, category 2A, Useful in certain circumstances recommendation:...Pembrolizumab or Nivolumab ± ipilimumab...For TMB-H (≥10 mutations/megabase [mut/Mb])l regardless of soft tissue sarcoma sub-type